News - Page 143 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

Post published:October 20, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders

Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders

Post published:October 20, 2021
Post category:Press Release

Read more about the article Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Post published:October 19, 2021
Post category:Press Release

Read more about the article Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton

Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton

Post published:October 19, 2021
Post category:Press Release

Read more about the article Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation

Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation

Post published:October 19, 2021
Post category:Press Release

Read more about the article Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Post published:October 19, 2021
Post category:Press Release

Read more about the article First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

Post published:October 19, 2021
Post category:Press Release

Read more about the article PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

Post published:October 19, 2021
Post category:Press Release

Read more about the article COMPASS Pathways is granted new US patent for crystalline psilocybin

COMPASS Pathways is granted new US patent for crystalline psilocybin

Post published:October 19, 2021
Post category:Press Release

Read more about the article atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change

atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change

Post published:October 19, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.